Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations

Pharmacy, Oncology, Clinical Data Management +16

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun et al. · Journal of Clinical Oncology · 2001 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

Jean‐Marc Nabholtz, Aman U. Buzdar, Michaël Pollak et al. · Journal of Clinical Oncology · 2000 · 996 citations

Pharmacy, Oncology, Pharmacotherapy +15

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

Jacques Bonneterre, Beat Thürlimann, J.F.R. Robertson et al. · Journal of Clinical Oncology · 2000 · 840 citations

Medicine, Oncology, Pharmacology +15

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

P Dombernowsky, I E Smith, Geoffrey Falkson et al. · Journal of Clinical Oncology · 1998 · 640 citations

Medicine, Oncology, Pharmacology +16